| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hematopoietic Stem Cell Transplantation | 115 | 2024 | 7009 | 5.490 |
Why?
|
| Graft vs Host Disease | 69 | 2024 | 2808 | 5.450 |
Why?
|
| Transplantation Conditioning | 56 | 2023 | 2368 | 3.030 |
Why?
|
| Leukemia, Myeloid, Acute | 31 | 2024 | 7259 | 1.970 |
Why?
|
| Myeloablative Agonists | 10 | 2021 | 386 | 1.600 |
Why?
|
| Transplantation, Homologous | 56 | 2024 | 3041 | 1.410 |
Why?
|
| Hematologic Neoplasms | 20 | 2022 | 1948 | 1.410 |
Why?
|
| Myelodysplastic Syndromes | 19 | 2024 | 3149 | 1.380 |
Why?
|
| Multiple Myeloma | 24 | 2023 | 2281 | 1.230 |
Why?
|
| Stem Cell Transplantation | 22 | 2021 | 1413 | 1.180 |
Why?
|
| Mycophenolic Acid | 4 | 2024 | 153 | 1.110 |
Why?
|
| Cord Blood Stem Cell Transplantation | 7 | 2018 | 372 | 1.010 |
Why?
|
| Cyclophosphamide | 21 | 2024 | 3242 | 1.000 |
Why?
|
| Transplantation, Autologous | 33 | 2023 | 2045 | 0.990 |
Why?
|
| Cytomegalovirus Infections | 4 | 2024 | 491 | 0.960 |
Why?
|
| Melphalan | 21 | 2019 | 875 | 0.830 |
Why?
|
| Busulfan | 8 | 2021 | 792 | 0.770 |
Why?
|
| Aged | 105 | 2024 | 73126 | 0.760 |
Why?
|
| Antilymphocyte Serum | 6 | 2022 | 237 | 0.760 |
Why?
|
| Lymphocyte Depletion | 3 | 2018 | 316 | 0.740 |
Why?
|
| Transplants | 1 | 2021 | 50 | 0.740 |
Why?
|
| Vidarabine | 21 | 2019 | 1383 | 0.730 |
Why?
|
| Middle Aged | 126 | 2024 | 90027 | 0.710 |
Why?
|
| Histocompatibility Testing | 7 | 2018 | 486 | 0.680 |
Why?
|
| Carbapenem-Resistant Enterobacteriaceae | 1 | 2019 | 6 | 0.680 |
Why?
|
| Adult | 114 | 2024 | 81690 | 0.680 |
Why?
|
| Vancomycin-Resistant Enterococci | 1 | 2019 | 20 | 0.670 |
Why?
|
| Health Facility Closure | 1 | 2019 | 9 | 0.670 |
Why?
|
| Epidemiological Monitoring | 1 | 2019 | 83 | 0.650 |
Why?
|
| Enterobacteriaceae Infections | 1 | 2019 | 70 | 0.640 |
Why?
|
| Gram-Positive Bacterial Infections | 1 | 2019 | 163 | 0.600 |
Why?
|
| Allografts | 10 | 2021 | 686 | 0.600 |
Why?
|
| HLA-DRB1 Chains | 1 | 2018 | 89 | 0.600 |
Why?
|
| Recurrence | 29 | 2023 | 4873 | 0.590 |
Why?
|
| B-Cell Activating Factor | 1 | 2017 | 26 | 0.580 |
Why?
|
| Retrospective Studies | 65 | 2024 | 39733 | 0.580 |
Why?
|
| Male | 120 | 2024 | 127911 | 0.570 |
Why?
|
| Humans | 160 | 2024 | 270014 | 0.560 |
Why?
|
| Body Fluids | 1 | 2017 | 121 | 0.550 |
Why?
|
| Disease-Free Survival | 38 | 2021 | 10258 | 0.550 |
Why?
|
| Female | 122 | 2024 | 148480 | 0.530 |
Why?
|
| Edema | 1 | 2017 | 263 | 0.510 |
Why?
|
| Acute Disease | 14 | 2024 | 2489 | 0.510 |
Why?
|
| Tacrolimus | 8 | 2022 | 345 | 0.510 |
Why?
|
| Methylprednisolone | 4 | 2011 | 196 | 0.510 |
Why?
|
| Remission Induction | 23 | 2024 | 3648 | 0.500 |
Why?
|
| Real-Time Polymerase Chain Reaction | 1 | 2019 | 1197 | 0.500 |
Why?
|
| Kidney Transplantation | 1 | 2021 | 758 | 0.500 |
Why?
|
| Tissue Donors | 9 | 2022 | 812 | 0.480 |
Why?
|
| Survival Analysis | 25 | 2021 | 9288 | 0.470 |
Why?
|
| Weight Gain | 1 | 2017 | 472 | 0.460 |
Why?
|
| T-Lymphocytes | 7 | 2018 | 3939 | 0.450 |
Why?
|
| Histocompatibility | 7 | 2022 | 183 | 0.450 |
Why?
|
| Antibodies, Monoclonal | 13 | 2012 | 4462 | 0.450 |
Why?
|
| Survival Rate | 33 | 2021 | 12508 | 0.450 |
Why?
|
| Adolescent | 45 | 2024 | 32646 | 0.440 |
Why?
|
| Peripheral Blood Stem Cell Transplantation | 6 | 2017 | 218 | 0.440 |
Why?
|
| Treatment Outcome | 59 | 2024 | 33690 | 0.430 |
Why?
|
| Young Adult | 33 | 2024 | 22134 | 0.410 |
Why?
|
| Bone Marrow Transplantation | 7 | 2021 | 1755 | 0.400 |
Why?
|
| Unrelated Donors | 5 | 2023 | 321 | 0.390 |
Why?
|
| Virus Diseases | 2 | 2015 | 392 | 0.390 |
Why?
|
| Hodgkin Disease | 7 | 2017 | 1485 | 0.360 |
Why?
|
| Risk Factors | 27 | 2024 | 17824 | 0.350 |
Why?
|
| Transplantation, Haploidentical | 3 | 2022 | 159 | 0.340 |
Why?
|
| Lymphoma | 6 | 2019 | 1517 | 0.320 |
Why?
|
| Bone Marrow | 6 | 2021 | 2437 | 0.320 |
Why?
|
| Birth Weight | 2 | 2001 | 354 | 0.320 |
Why?
|
| Cytomegalovirus | 2 | 2024 | 493 | 0.320 |
Why?
|
| Graft Survival | 9 | 2017 | 1079 | 0.300 |
Why?
|
| Siblings | 3 | 2022 | 318 | 0.300 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 22 | 2017 | 16640 | 0.300 |
Why?
|
| Prognosis | 24 | 2024 | 22451 | 0.300 |
Why?
|
| Gastrointestinal Diseases | 3 | 2024 | 598 | 0.300 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2011 | 449 | 0.290 |
Why?
|
| Killer Cells, Natural | 3 | 2018 | 965 | 0.280 |
Why?
|
| Virus Activation | 3 | 2018 | 236 | 0.280 |
Why?
|
| Hematopoietic Stem Cell Mobilization | 4 | 2009 | 270 | 0.270 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 7 | 2024 | 2895 | 0.270 |
Why?
|
| fms-Like Tyrosine Kinase 3 | 2 | 2024 | 838 | 0.260 |
Why?
|
| Hematopoiesis | 1 | 2008 | 601 | 0.250 |
Why?
|
| Philadelphia Chromosome | 2 | 2024 | 845 | 0.240 |
Why?
|
| Graft Rejection | 2 | 2010 | 843 | 0.240 |
Why?
|
| Incidence | 14 | 2024 | 5806 | 0.240 |
Why?
|
| Predictive Value of Tests | 6 | 2019 | 4944 | 0.240 |
Why?
|
| Seizures | 2 | 2001 | 1032 | 0.240 |
Why?
|
| Minnesota | 1 | 2024 | 126 | 0.240 |
Why?
|
| Neoplastic Cells, Circulating | 1 | 2008 | 637 | 0.220 |
Why?
|
| Immunosuppressive Agents | 6 | 2024 | 1426 | 0.220 |
Why?
|
| Amyloidosis | 2 | 2015 | 173 | 0.220 |
Why?
|
| Salvage Therapy | 7 | 2017 | 2122 | 0.220 |
Why?
|
| Mesenchymal Stem Cell Transplantation | 2 | 2017 | 205 | 0.220 |
Why?
|
| Hepatic Veno-Occlusive Disease | 1 | 2024 | 135 | 0.210 |
Why?
|
| Aniline Compounds | 1 | 2024 | 205 | 0.210 |
Why?
|
| Maintenance Chemotherapy | 1 | 2024 | 224 | 0.210 |
Why?
|
| Neoplasm, Residual | 5 | 2022 | 1742 | 0.200 |
Why?
|
| Bronchiolitis Obliterans | 1 | 2022 | 94 | 0.200 |
Why?
|
| Vascular Diseases | 1 | 2024 | 235 | 0.190 |
Why?
|
| Pyrazines | 1 | 2024 | 510 | 0.190 |
Why?
|
| Proportional Hazards Models | 6 | 2023 | 5099 | 0.190 |
Why?
|
| Follow-Up Studies | 21 | 2021 | 15172 | 0.190 |
Why?
|
| Neutrophils | 3 | 2017 | 834 | 0.180 |
Why?
|
| Child, Preschool | 12 | 2023 | 16984 | 0.180 |
Why?
|
| Lymphoma, Non-Hodgkin | 4 | 2008 | 1066 | 0.160 |
Why?
|
| NK Cell Lectin-Like Receptor Subfamily C | 1 | 2018 | 22 | 0.160 |
Why?
|
| Chronic Disease | 7 | 2017 | 1808 | 0.160 |
Why?
|
| Blood Platelets | 4 | 2012 | 671 | 0.160 |
Why?
|
| Immunoglobulin Light-chain Amyloidosis | 1 | 2018 | 31 | 0.160 |
Why?
|
| Neoplasms, Second Primary | 2 | 2017 | 1387 | 0.160 |
Why?
|
| Blood Donors | 3 | 2013 | 173 | 0.150 |
Why?
|
| Blood Transfusion | 1 | 2021 | 581 | 0.150 |
Why?
|
| Blast Crisis | 1 | 2021 | 587 | 0.150 |
Why?
|
| Induction Chemotherapy | 2 | 2018 | 670 | 0.150 |
Why?
|
| Donor Selection | 2 | 2022 | 108 | 0.150 |
Why?
|
| Pentostatin | 1 | 2017 | 121 | 0.150 |
Why?
|
| Lymphoma, Mantle-Cell | 3 | 2013 | 749 | 0.150 |
Why?
|
| Steroids | 4 | 2020 | 371 | 0.150 |
Why?
|
| Incidental Findings | 1 | 2019 | 282 | 0.150 |
Why?
|
| Antimetabolites, Antineoplastic | 1 | 2024 | 1347 | 0.150 |
Why?
|
| Leukapheresis | 3 | 2013 | 166 | 0.140 |
Why?
|
| Azacitidine | 1 | 2024 | 1217 | 0.140 |
Why?
|
| Tumor Burden | 3 | 2008 | 2031 | 0.140 |
Why?
|
| Granulocyte Colony-Stimulating Factor | 4 | 2009 | 770 | 0.140 |
Why?
|
| Immunity, Innate | 1 | 2021 | 700 | 0.140 |
Why?
|
| Hepatitis B Antibodies | 1 | 2017 | 56 | 0.140 |
Why?
|
| Molecular Diagnostic Techniques | 1 | 2019 | 334 | 0.140 |
Why?
|
| Fetal Blood | 2 | 2017 | 501 | 0.140 |
Why?
|
| Cystitis | 2 | 2010 | 109 | 0.130 |
Why?
|
| Antibodies, Monoclonal, Murine-Derived | 9 | 2013 | 878 | 0.130 |
Why?
|
| Hospitals | 1 | 2019 | 482 | 0.130 |
Why?
|
| Lymphoma, Follicular | 3 | 2012 | 636 | 0.130 |
Why?
|
| Immunoglobulin lambda-Chains | 1 | 2015 | 43 | 0.130 |
Why?
|
| Chromosome Aberrations | 2 | 2020 | 2031 | 0.130 |
Why?
|
| Lymphoma, Large B-Cell, Diffuse | 2 | 2021 | 1737 | 0.130 |
Why?
|
| Leukemia, Myeloid | 3 | 2010 | 993 | 0.130 |
Why?
|
| Child | 19 | 2022 | 30460 | 0.130 |
Why?
|
| Photopheresis | 2 | 2006 | 79 | 0.130 |
Why?
|
| Infliximab | 3 | 2011 | 138 | 0.120 |
Why?
|
| Cohort Studies | 6 | 2020 | 9463 | 0.120 |
Why?
|
| Combined Modality Therapy | 12 | 2020 | 9039 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2018 | 3653 | 0.120 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2015 | 104 | 0.120 |
Why?
|
| Gastrointestinal Tract | 1 | 2017 | 318 | 0.120 |
Why?
|
| Lymphocyte Transfusion | 2 | 2013 | 174 | 0.120 |
Why?
|
| Outpatients | 1 | 2017 | 460 | 0.120 |
Why?
|
| Risk | 2 | 2017 | 1937 | 0.120 |
Why?
|
| Leukocyte Transfusion | 2 | 2012 | 44 | 0.120 |
Why?
|
| Multivariate Analysis | 5 | 2017 | 4318 | 0.110 |
Why?
|
| Pulmonary Disease, Chronic Obstructive | 1 | 2022 | 1061 | 0.110 |
Why?
|
| Rituximab | 9 | 2013 | 1590 | 0.110 |
Why?
|
| Myeloproliferative Disorders | 1 | 2021 | 881 | 0.110 |
Why?
|
| Blood Volume | 1 | 2013 | 106 | 0.110 |
Why?
|
| Mortality | 1 | 2015 | 347 | 0.110 |
Why?
|
| Blood Grouping and Crossmatching | 1 | 2013 | 35 | 0.110 |
Why?
|
| Ganciclovir | 1 | 2013 | 194 | 0.110 |
Why?
|
| SOXC Transcription Factors | 1 | 2013 | 58 | 0.110 |
Why?
|
| Antigens, Viral | 1 | 2015 | 518 | 0.110 |
Why?
|
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2016 | 331 | 0.110 |
Why?
|
| Deoxycytidine | 2 | 2016 | 1389 | 0.110 |
Why?
|
| Thiotepa | 5 | 2013 | 132 | 0.110 |
Why?
|
| Case-Control Studies | 6 | 2024 | 6204 | 0.100 |
Why?
|
| Prospective Studies | 8 | 2018 | 13378 | 0.100 |
Why?
|
| Alleles | 3 | 2015 | 2590 | 0.100 |
Why?
|
| Inpatients | 1 | 2017 | 686 | 0.100 |
Why?
|
| Antineoplastic Agents | 9 | 2009 | 14613 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 14 | 1 | 2013 | 287 | 0.100 |
Why?
|
| Lymphoma, T-Cell | 1 | 2015 | 366 | 0.100 |
Why?
|
| Patient Selection | 2 | 2017 | 2026 | 0.100 |
Why?
|
| Disease Progression | 8 | 2024 | 6840 | 0.100 |
Why?
|
| Chromosomes, Human, Pair 11 | 1 | 2013 | 413 | 0.100 |
Why?
|
| Neoplasm Recurrence, Local | 6 | 2022 | 10382 | 0.100 |
Why?
|
| Autografts | 3 | 2017 | 179 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 4 | 2007 | 2475 | 0.090 |
Why?
|
| Ki-67 Antigen | 1 | 2013 | 675 | 0.090 |
Why?
|
| B-Lymphocytes | 2 | 2015 | 1423 | 0.090 |
Why?
|
| Hepacivirus | 2 | 2016 | 421 | 0.090 |
Why?
|
| Thalidomide | 2 | 2017 | 595 | 0.090 |
Why?
|
| Transplantation Chimera | 4 | 2015 | 173 | 0.090 |
Why?
|
| Hepatitis C | 1 | 2016 | 547 | 0.090 |
Why?
|
| Precursor B-Cell Lymphoblastic Leukemia-Lymphoma | 2 | 2024 | 513 | 0.090 |
Why?
|
| Immunologic Factors | 3 | 2016 | 671 | 0.090 |
Why?
|
| Kidney Diseases | 1 | 2015 | 689 | 0.090 |
Why?
|
| Vitamin D Deficiency | 1 | 2011 | 121 | 0.090 |
Why?
|
| Leukemia | 3 | 2010 | 1719 | 0.080 |
Why?
|
| Osteoporosis | 1 | 2011 | 232 | 0.080 |
Why?
|
| Vitamin D | 1 | 2011 | 261 | 0.080 |
Why?
|
| Age Factors | 5 | 2017 | 5448 | 0.080 |
Why?
|
| Glomerular Filtration Rate | 2 | 2009 | 592 | 0.080 |
Why?
|
| BK Virus | 1 | 2010 | 126 | 0.080 |
Why?
|
| Platelet Transfusion | 2 | 2007 | 166 | 0.080 |
Why?
|
| Polyomavirus Infections | 1 | 2010 | 146 | 0.080 |
Why?
|
| Primary Myelofibrosis | 2 | 2010 | 913 | 0.080 |
Why?
|
| Body Weight | 1 | 2013 | 1306 | 0.080 |
Why?
|
| Clinical Trials as Topic | 4 | 2020 | 3841 | 0.080 |
Why?
|
| Time Factors | 10 | 2020 | 12952 | 0.080 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 30923 | 0.080 |
Why?
|
| Tumor Virus Infections | 1 | 2010 | 247 | 0.080 |
Why?
|
| Models, Biological | 1 | 2017 | 3187 | 0.080 |
Why?
|
| Ascorbic Acid | 1 | 2008 | 131 | 0.080 |
Why?
|
| Kinetics | 2 | 2008 | 2186 | 0.080 |
Why?
|
| Infant, Premature, Diseases | 2 | 2001 | 258 | 0.080 |
Why?
|
| Oxides | 1 | 2008 | 212 | 0.080 |
Why?
|
| Arsenicals | 1 | 2008 | 205 | 0.070 |
Why?
|
| Translocation, Genetic | 1 | 2013 | 1285 | 0.070 |
Why?
|
| HLA Antigens | 1 | 2010 | 593 | 0.070 |
Why?
|
| Holmium | 1 | 2007 | 24 | 0.070 |
Why?
|
| ZAP-70 Protein-Tyrosine Kinase | 1 | 2007 | 103 | 0.070 |
Why?
|
| Hepatitis B | 1 | 2010 | 273 | 0.070 |
Why?
|
| Stroke Volume | 1 | 2009 | 535 | 0.070 |
Why?
|
| Leukocyte Count | 1 | 2008 | 724 | 0.070 |
Why?
|
| Organophosphorus Compounds | 1 | 2007 | 90 | 0.070 |
Why?
|
| Graft vs Tumor Effect | 4 | 2012 | 143 | 0.070 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2013 | 1365 | 0.070 |
Why?
|
| Chi-Square Distribution | 4 | 2017 | 1309 | 0.070 |
Why?
|
| Leukemia, Myelomonocytic, Chronic | 2 | 2017 | 460 | 0.070 |
Why?
|
| Graft vs Leukemia Effect | 1 | 2007 | 107 | 0.070 |
Why?
|
| Erythroid Precursor Cells | 1 | 2006 | 70 | 0.070 |
Why?
|
| Gestational Age | 2 | 2001 | 1173 | 0.070 |
Why?
|
| Blood Cells | 1 | 2006 | 129 | 0.070 |
Why?
|
| Renal Insufficiency | 1 | 2009 | 309 | 0.070 |
Why?
|
| Burkitt Lymphoma | 2 | 2006 | 348 | 0.070 |
Why?
|
| Antiviral Agents | 1 | 2013 | 1250 | 0.070 |
Why?
|
| Radioisotopes | 1 | 2007 | 175 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 1 | 1 | 2007 | 354 | 0.070 |
Why?
|
| Recovery of Function | 1 | 2009 | 682 | 0.060 |
Why?
|
| Antioxidants | 1 | 2008 | 520 | 0.060 |
Why?
|
| Muscular Diseases | 1 | 2006 | 161 | 0.060 |
Why?
|
| Primary Ovarian Insufficiency | 1 | 2005 | 65 | 0.060 |
Why?
|
| Whole-Body Irradiation | 3 | 2017 | 322 | 0.060 |
Why?
|
| Kaplan-Meier Estimate | 4 | 2019 | 6253 | 0.060 |
Why?
|
| Infant, Premature | 2 | 2001 | 843 | 0.060 |
Why?
|
| Neovascularization, Physiologic | 1 | 2006 | 341 | 0.060 |
Why?
|
| Methotrexate | 3 | 2022 | 1025 | 0.060 |
Why?
|
| Vincristine | 2 | 2009 | 1581 | 0.060 |
Why?
|
| Hemorrhagic Disorders | 1 | 2004 | 52 | 0.060 |
Why?
|
| Lymphocytes | 1 | 2008 | 1272 | 0.060 |
Why?
|
| CD8-Positive T-Lymphocytes | 2 | 2003 | 1654 | 0.060 |
Why?
|
| Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative | 1 | 2004 | 121 | 0.060 |
Why?
|
| Heart Diseases | 1 | 2009 | 718 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 194 | 0.050 |
Why?
|
| Antibodies, Neoplasm | 1 | 2004 | 273 | 0.050 |
Why?
|
| Blood Cell Count | 2 | 2013 | 233 | 0.050 |
Why?
|
| Dexamethasone | 2 | 2009 | 1506 | 0.050 |
Why?
|
| Texas | 3 | 2012 | 6430 | 0.050 |
Why?
|
| Chromosome Deletion | 1 | 2007 | 1049 | 0.050 |
Why?
|
| Protein Kinase Inhibitors | 2 | 2024 | 4958 | 0.050 |
Why?
|
| Cause of Death | 2 | 2017 | 778 | 0.050 |
Why?
|
| Acute Kidney Injury | 1 | 2009 | 758 | 0.050 |
Why?
|
| Glucocorticoids | 1 | 2005 | 618 | 0.050 |
Why?
|
| Filgrastim | 3 | 2009 | 194 | 0.050 |
Why?
|
| Biopsy | 2 | 2020 | 3384 | 0.050 |
Why?
|
| Lower Gastrointestinal Tract | 1 | 2020 | 29 | 0.050 |
Why?
|
| Sirolimus | 1 | 2005 | 831 | 0.050 |
Why?
|
| Ferritins | 1 | 2021 | 155 | 0.050 |
Why?
|
| Doxorubicin | 2 | 2009 | 3142 | 0.050 |
Why?
|
| Infant, Low Birth Weight | 1 | 2001 | 173 | 0.050 |
Why?
|
| Cardiotoxicity | 1 | 2021 | 151 | 0.050 |
Why?
|
| Feasibility Studies | 2 | 2020 | 2358 | 0.040 |
Why?
|
| Endothelial Cells | 1 | 2006 | 1036 | 0.040 |
Why?
|
| Etoposide | 3 | 2009 | 905 | 0.040 |
Why?
|
| Azithromycin | 1 | 2020 | 78 | 0.040 |
Why?
|
| Receptors, Cytokine | 1 | 2021 | 178 | 0.040 |
Why?
|
| Recombinant Proteins | 4 | 2009 | 3023 | 0.040 |
Why?
|
| HLA-DQ Antigens | 1 | 2000 | 56 | 0.040 |
Why?
|
| HLA-DR Antigens | 1 | 2000 | 183 | 0.040 |
Why?
|
| Stem Cells | 1 | 2006 | 1211 | 0.040 |
Why?
|
| Mothers | 1 | 2022 | 416 | 0.040 |
Why?
|
| Positron-Emission Tomography | 1 | 2008 | 2196 | 0.040 |
Why?
|
| Butyrophenones | 1 | 2019 | 13 | 0.040 |
Why?
|
| Statistics, Nonparametric | 3 | 2007 | 981 | 0.040 |
Why?
|
| Immunologic Surveillance | 1 | 2018 | 59 | 0.040 |
Why?
|
| Cytogenetic Analysis | 1 | 2020 | 574 | 0.040 |
Why?
|
| Topotecan | 2 | 2010 | 248 | 0.040 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2004 | 1570 | 0.040 |
Why?
|
| Antigens, CD34 | 2 | 2013 | 637 | 0.040 |
Why?
|
| Fusion Proteins, bcr-abl | 1 | 2004 | 1143 | 0.040 |
Why?
|
| CD5 Antigens | 1 | 1999 | 129 | 0.040 |
Why?
|
| CD4-Positive T-Lymphocytes | 1 | 2003 | 1052 | 0.040 |
Why?
|
| Infant, Very Low Birth Weight | 1 | 1999 | 171 | 0.040 |
Why?
|
| Lymphoma, B-Cell | 1 | 2005 | 928 | 0.040 |
Why?
|
| Transplant Recipients | 1 | 2020 | 336 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2018 | 2843 | 0.040 |
Why?
|
| Anemia, Refractory, with Excess of Blasts | 1 | 2017 | 88 | 0.040 |
Why?
|
| Infant, Newborn | 2 | 2001 | 8671 | 0.040 |
Why?
|
| Monosomy | 1 | 2017 | 98 | 0.040 |
Why?
|
| Ifosfamide | 2 | 2009 | 357 | 0.040 |
Why?
|
| Pneumonia | 1 | 2003 | 795 | 0.030 |
Why?
|
| Survivors | 3 | 2007 | 1022 | 0.030 |
Why?
|
| Myeloma Proteins | 1 | 2015 | 27 | 0.030 |
Why?
|
| Premedication | 1 | 2016 | 133 | 0.030 |
Why?
|
| Preoperative Period | 1 | 2017 | 347 | 0.030 |
Why?
|
| Gene Dosage | 1 | 2018 | 823 | 0.030 |
Why?
|
| Histocompatibility Antigens | 1 | 2015 | 79 | 0.030 |
Why?
|
| Endoscopy, Gastrointestinal | 1 | 2017 | 350 | 0.030 |
Why?
|
| In Situ Hybridization, Fluorescence | 1 | 2020 | 2308 | 0.030 |
Why?
|
| Proteasome Inhibitors | 1 | 2016 | 232 | 0.030 |
Why?
|
| Cell Separation | 1 | 2017 | 608 | 0.030 |
Why?
|
| Biomarkers, Tumor | 2 | 2020 | 10694 | 0.030 |
Why?
|
| Adoptive Transfer | 1 | 2017 | 431 | 0.030 |
Why?
|
| Retreatment | 1 | 2015 | 447 | 0.030 |
Why?
|
| Hemorrhage | 2 | 2010 | 726 | 0.030 |
Why?
|
| Carmustine | 2 | 2005 | 224 | 0.030 |
Why?
|
| Nausea | 1 | 2016 | 540 | 0.030 |
Why?
|
| Reoperation | 1 | 2018 | 1390 | 0.030 |
Why?
|
| Viral Load | 1 | 2016 | 484 | 0.030 |
Why?
|
| Prevalence | 2 | 2016 | 3353 | 0.030 |
Why?
|
| Cytarabine | 2 | 2013 | 2013 | 0.030 |
Why?
|
| Cytogenetics | 1 | 2013 | 152 | 0.030 |
Why?
|
| Graft Enhancement, Immunologic | 1 | 2012 | 38 | 0.030 |
Why?
|
| Antibodies, Monoclonal, Humanized | 2 | 2020 | 3398 | 0.030 |
Why?
|
| Severity of Illness Index | 2 | 2017 | 4360 | 0.030 |
Why?
|
| Skin Diseases | 1 | 2016 | 366 | 0.030 |
Why?
|
| Human Experimentation | 1 | 2013 | 51 | 0.030 |
Why?
|
| Immunoconjugates | 1 | 2016 | 314 | 0.030 |
Why?
|
| Liver Diseases | 1 | 2017 | 599 | 0.030 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2004 | 2633 | 0.030 |
Why?
|
| Immunotherapy, Adoptive | 1 | 2001 | 1840 | 0.020 |
Why?
|
| Radioimmunotherapy | 1 | 2012 | 128 | 0.020 |
Why?
|
| Gene Deletion | 1 | 2016 | 1472 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2011 | 245 | 0.020 |
Why?
|
| Parathyroid Hormone | 1 | 2011 | 184 | 0.020 |
Why?
|
| Transplantation | 1 | 2010 | 56 | 0.020 |
Why?
|
| Flow Cytometry | 1 | 2017 | 3037 | 0.020 |
Why?
|
| Drug Therapy, Combination | 2 | 2007 | 2325 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 1 | 2017 | 3468 | 0.020 |
Why?
|
| Yttrium Radioisotopes | 1 | 2012 | 210 | 0.020 |
Why?
|
| Comorbidity | 1 | 2017 | 2389 | 0.020 |
Why?
|
| Lung Diseases | 1 | 2016 | 751 | 0.020 |
Why?
|
| Demography | 1 | 2011 | 430 | 0.020 |
Why?
|
| Cell Culture Techniques | 1 | 2012 | 573 | 0.020 |
Why?
|
| Haplotypes | 1 | 2012 | 910 | 0.020 |
Why?
|
| Infant | 2 | 2015 | 13945 | 0.020 |
Why?
|
| Benzylamines | 1 | 2009 | 98 | 0.020 |
Why?
|
| Heterocyclic Compounds | 1 | 2009 | 117 | 0.020 |
Why?
|
| Bone Density | 1 | 2011 | 467 | 0.020 |
Why?
|
| Gallium Radioisotopes | 1 | 2008 | 62 | 0.020 |
Why?
|
| Ovarian Neoplasms | 1 | 2004 | 4784 | 0.020 |
Why?
|
| Scleroderma, Systemic | 1 | 2009 | 165 | 0.020 |
Why?
|
| Hospitals, University | 1 | 2008 | 218 | 0.020 |
Why?
|
| Whole Body Imaging | 1 | 2008 | 120 | 0.020 |
Why?
|
| Mutation | 2 | 2018 | 15900 | 0.020 |
Why?
|
| Creatinine | 1 | 2009 | 528 | 0.020 |
Why?
|
| Biomarkers | 1 | 2018 | 5046 | 0.020 |
Why?
|
| Cancer Care Facilities | 1 | 2012 | 907 | 0.020 |
Why?
|
| Forms and Records Control | 1 | 2006 | 24 | 0.020 |
Why?
|
| Platelet Count | 1 | 2007 | 490 | 0.020 |
Why?
|
| Regression Analysis | 1 | 2009 | 1568 | 0.020 |
Why?
|
| Antigens, CD20 | 1 | 2006 | 207 | 0.020 |
Why?
|
| Antigens, Differentiation | 1 | 2006 | 245 | 0.020 |
Why?
|
| Treatment Failure | 1 | 2009 | 1426 | 0.020 |
Why?
|
| Calcium | 1 | 2011 | 1540 | 0.020 |
Why?
|
| Mouth Mucosa | 1 | 2005 | 224 | 0.020 |
Why?
|
| Aging | 1 | 2013 | 1525 | 0.020 |
Why?
|
| Injections, Subcutaneous | 1 | 2005 | 341 | 0.010 |
Why?
|
| United States Food and Drug Administration | 1 | 2006 | 323 | 0.010 |
Why?
|
| Medical Records | 1 | 2006 | 442 | 0.010 |
Why?
|
| CD52 Antigen | 1 | 2004 | 47 | 0.010 |
Why?
|
| Multicenter Studies as Topic | 1 | 2006 | 558 | 0.010 |
Why?
|
| Drug Resistance | 1 | 2005 | 609 | 0.010 |
Why?
|
| Anemia, Aplastic | 1 | 2005 | 232 | 0.010 |
Why?
|
| Eye | 1 | 2005 | 283 | 0.010 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2006 | 499 | 0.010 |
Why?
|
| Patients | 1 | 2006 | 246 | 0.010 |
Why?
|
| Protein-Tyrosine Kinases | 1 | 2011 | 1837 | 0.010 |
Why?
|
| Alemtuzumab | 1 | 2004 | 213 | 0.010 |
Why?
|
| Data Collection | 1 | 2006 | 608 | 0.010 |
Why?
|
| Hyperlipidemias | 1 | 2005 | 223 | 0.010 |
Why?
|
| Ischemia | 1 | 2006 | 399 | 0.010 |
Why?
|
| Forecasting | 1 | 2006 | 699 | 0.010 |
Why?
|
| Clinical Trials, Phase II as Topic | 1 | 2006 | 686 | 0.010 |
Why?
|
| Lymphoproliferative Disorders | 1 | 2005 | 381 | 0.010 |
Why?
|
| CD4 Lymphocyte Count | 1 | 2003 | 294 | 0.010 |
Why?
|
| Time | 1 | 2003 | 183 | 0.010 |
Why?
|
| Radiopharmaceuticals | 1 | 2008 | 1341 | 0.010 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2006 | 564 | 0.010 |
Why?
|
| Breast Neoplasms | 2 | 2005 | 16182 | 0.010 |
Why?
|
| Neoplasms | 2 | 2006 | 15899 | 0.010 |
Why?
|
| Fluorodeoxyglucose F18 | 1 | 2008 | 1260 | 0.010 |
Why?
|
| Infusions, Intravenous | 1 | 2005 | 1435 | 0.010 |
Why?
|
| Lymphocyte Count | 1 | 2003 | 485 | 0.010 |
Why?
|
| Anemia, Sickle Cell | 1 | 2005 | 364 | 0.010 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 1265 | 0.010 |
Why?
|
| United States | 2 | 2011 | 15776 | 0.010 |
Why?
|
| Immune Tolerance | 1 | 2004 | 423 | 0.010 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2010 | 2448 | 0.010 |
Why?
|
| Thrombocytopenia | 1 | 2005 | 870 | 0.010 |
Why?
|
| Mycoses | 1 | 2004 | 393 | 0.010 |
Why?
|
| Glycoproteins | 1 | 2004 | 778 | 0.010 |
Why?
|
| Bacterial Infections | 1 | 2004 | 508 | 0.010 |
Why?
|
| Skin | 1 | 2005 | 1270 | 0.010 |
Why?
|
| Neoplasm Staging | 1 | 2015 | 13994 | 0.010 |
Why?
|
| Genes, MHC Class II | 1 | 2000 | 71 | 0.010 |
Why?
|
| Syndrome | 1 | 2003 | 1405 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2008 | 5062 | 0.010 |
Why?
|
| Antigens, CD | 1 | 2004 | 1411 | 0.010 |
Why?
|
| Research Design | 1 | 2006 | 1569 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2005 | 1469 | 0.010 |
Why?
|
| Antigens, Neoplasm | 1 | 2004 | 1580 | 0.010 |
Why?
|
| Liver | 1 | 2005 | 3069 | 0.010 |
Why?
|
| Bone Marrow Cells | 1 | 1999 | 965 | 0.010 |
Why?
|
| Surveys and Questionnaires | 1 | 2005 | 5907 | 0.010 |
Why?
|
| Animals | 2 | 2009 | 61707 | 0.010 |
Why?
|
| Mice | 1 | 2003 | 35461 | 0.000 |
Why?
|